We are live on ! Find out more
CASI icon

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

50 hedge funds and large institutions have $37.3M invested in CASI Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital inflows, than outflows

Capital inflows: $2.82M | Capital outflows: $1.48M

90% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 10

0.13% more ownership

Funds ownership: 12.04% → 12.17% (+0.13%)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

4% less funds holding

Funds holding: 52 → 50 (-2)

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
19
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.19M
2
Nuveen
Nuveen
North Carolina
+$655K
3
State Street
State Street
Massachusetts
+$241K
4
Charles Schwab
Charles Schwab
California
+$190K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$127K

Top Sellers

Rank Fund Capital Flow
1
ALPS Advisors
ALPS Advisors
Colorado
-$661K
2
Deutsche Bank
Deutsche Bank
Germany
-$209K
3
Winton Group
Winton Group
United Kingdom
-$145K
4
Renaissance Technologies
Renaissance Technologies
New York
-$120K
5
Goldman Sachs
Goldman Sachs
New York
-$48.7K

CASI Hedge Fund Activity: Q2 2019 in Review

50 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2019, worth a combined $37.3M — up 13% from $32.9M a quarter earlier.

Fund positioning in CASI was balanced in Q2 2019: 6 funds opened new positions, 6 closed out, 19 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $1.19M. The largest seller was ALPS Advisors, exiting entirely with an estimated $661K sold.

  • 50 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2019, down from 52 in Q1 2019.
  • Funds reported $37.3M of CASI Pharmaceuticals stock for Q2 2019, up 13% quarter-over-quarter.
  • 6 funds opened new CASI Pharmaceuticals positions in Q2 2019 and 6 closed out, a net change of 0 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $1.19M added.
  • The largest CASI Pharmaceuticals seller in Q2 2019 was ALPS Advisors, an estimated $661K sold.

Based on aggregated 13F filings for Q2 2019.